Dublin, Nov. 28, 2017 (GLOBE NEWSWIRE) -- The "Botanical and Plant-Derived Drugs: Global Markets" report has been added to Research and Markets' offering.

The Global Market for Botanical and Plant-Derived Drugs will Grow from $29.4 Billion in 2017 to around $39.6 Billion by 2022 with a CAGR of 6.1%

Report Includes

• 27 tables
• An overview of the botanical drug industry, with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward
• Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
• A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall wellness rather than to address specific medical conditions or symptoms)
• Examination of the industry structure, competition, and market drivers
• Discussion of market size and segmentation, including breakdowns of sales by therapeutic area and geographic area
• Observations and conclusions regarding the future of the botanical and plant-derived drug industry

This report is an analytical business tool whose primary purpose is to describe the botanical drug industry with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward.

For the purposes of this report, botanicals are those drugs that are FDA-approved under the botanical drug pathway, while plant-derived drugs are both botanicals as well as other approved drugs that contain a mixture of natural plant-derived and synthetic or semisynthetic substances.

The study's main focus is on legal, prescription-required therapeutic medicines sold in the open market. The study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall wellness rather than to address a specific medical condition or symptoms). While there is a substantial market for these products, the medical value of many of these substances has not been demonstrated conclusively.

The Format Of The Study Is Organized Around The Following Topics:

• Major types and applications of botanical drugs with plant-derived drugs as their backdrop.
• Industry structure.
• Market size and segmentation, including the breakdown of sales by therapeutic area and geographic area.
• Market drivers.
• Market projections through 2022.
• Competition.
• Observations and conclusions regarding the future of the botanical and plant-derived drug industry.

Key Topics Covered:

1: Introduction

2: Summary and Highlights

• Trends and Drivers for Botanical Drug Development

3: Market and Technology Background

• Brief History of Plant-Derived Medicines
• Opportunity Lies Beyond What Is Known
• Getting Started
• Key Drivers
• Key Challenges
• U.S. Government Investment
• Industry Investment
• Nutrition Science Partners Ltd. (Nestle Health): A Case Study
• Botanical Drugs Defined
• Understanding the Regulatory Process
• Investigational New Drug Applications
• The First and Second U.S. Approved Botanical Drug
• Botanical Candidates in the Pipeline
• A Growing Pipeline
• Overall Pharma Landscape
• Major Classes of Plant Drugs
• Intellectual Property
• Production
• A New Type of Production: Plant-Made Drugs
• Drug Development and Manufacture

4: Market Breakdown by Technology Type

• Sales of Plant-derived Drugs by Region
• Plant-derived Drugs by Therapeutic Area
• Value of Plant-derived Drugs by Therapeutic Area
• A Pipeline Perspective: Composition of Botanical Drugs in Clinical Development

5: New Developments and Market Opportunities

• Hormone Therapy and Metabolism Applications
• Infectious Disease Applications
• Pain and Central Nervous System Disease Applications
• Cardiovascular and Metabolic Applications
• Respiratory, Inflammation (Both Nonrelated and Related to Orthopedic) and Autoimmune Applications
• Dermatology Applications
• Gastrointestinal Applications
• Oncology Applications
• Botanical Drugs in Clinical Development

6: Company Profiles

• Abbott Laboratories
• Artecef BV
• Bayer Healthcare Pharmaceuticals
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Cardax Pharmaceuticals
• Chi-Med
• Chong Kun Dang Pharmaceutical Corp.
• Eli Lilly
• Fytokem Products Inc.
• Galapagos Nv
• Glaxosmithkline
• Glenmark Pharmaceuticals Limited
• Heterogeneity Llc
• Hsrx Biopharmaceutical
• Indena
• Izun Pharmaceuticals Corp.
• Johnson & Johnson
• Lupin Pharmaceuticals Inc.
• Medigene Ag
• Merck & Co. Inc.
• Merlion Pharmaceuticals
• Microbio Co. Ltd.
• Mycosynthetix Inc.
• Napo Pharmaceuticals Inc.
• Novartis International AG
• Pfizer
• Pharmaceutical Plant Co.
• Phynova
• Sanofi
• Santalis Pharmaceuticals
• Schwabe Pharmaceuticals
• Sequoia Sciences Inc.
• Sun Pharmaceutical Industries Ltd.
• Yiviva

7: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/2w6xkn/botanical_and

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Pharmaceuticals

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.